disease of uterus
Conditions
Interventions
The Sufentanil group:Dilute Sufentanil 2ug/kg+ 0.9% sodium chloride to 100ml
Oxellidine low dose group:Oxelidine 0.1mg/kg+ 0.9% diluted to 100ml
Oxellidine medium dose group:Oxelidine 0.35mg/kg+ 0.9% diluted to 100ml
Oxellidine high dose group:Oxelidine 0.5mg/kg+ 0.9% diluted to 100ml
Sponsors
Shihezi University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18-65years ; 2. ASA grade I - II; 3. Be able to fill in and sign the informed consent in accordance with each rating scale
Exclusion criteria
Exclusion criteria: 1. Persons with a history of allergy to narcotic drugs and contraindications to opioids; 2. Severe respiratory depression ; 3. Patients with known or suspected gastrointestional obstruction; 4. Have a neurological disorder, long-term use of hypnotics or sedatives 5. Patients with moderate to severe hypertension and/or significantly elevated blood pressure that is life-threatening; 6. Patients with acute and chronic pain diseases; 7. Severe liver, liver and kidney dysfunction; 8. Refuse to sign informed consent, not the author
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative nausea and vomiting incidence rate;Postoperative adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative analgesic drug dosage;Systolic blood pressure, diastolic blood pressure, mean arterial pressure (MAP), and heart rate (HR);Effective number of presses of postoperative analgesia pump; | — |
Countries
China
Contacts
Public ContactDeng Jiaojiao
The First Affiliated Hospital of Shihezi University
Outcome results
None listed